Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05939336

MOS Prebiotic Potential in Older Adults

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Healthy

Age range

50 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Food Science and Human Nutrition Department, University of Florida

Gainesville, Florida, 32611, United States

About this study

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 50-99 years of age.
  • Able to provide written informed consent in English.
  • Willingness to complete all study procedures
  • Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion criteria

  • Yeast allergy.
  • Self-reported kidney disease.
  • Elite athletes or long-distance runners.
  • Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
  • Current use of laxatives or antidiarrheal medications.
  • Use of other investigational products within 3 months of the screening visit.
  • Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
  • Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
  • Current cancer treatment
  • Currently pregnant

Treatment and study plan

Mannooligosaccharides yeast extract

Dietary Supplement

15 g per day of mannooligosaccharide yeast extract.

Primary outcomes

  1. Mean daily rating of gastrointestinal symptoms

    Time frame: 14 days

    Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • Lallemand Bio-Ingredients

Registry information

Official study title

The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
Jul 11, 2023
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.